By Michael Smith, North American Correspondent, MedPage Today
Published: December 13, 2010
Reviewed by Zalman S. Agus, MD; Emeritus Professor
University of Pennsylvania School of Medicine and
Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner
Many girls and young women may not be completing all three doses of the quadrivalent human papillomavirus vaccine in a timely fashion, researchers reported.
In a single-institution retrospective analysis, only 14% of girls and young women completed all three doses within seven months of the first, and only 28% did so within 12 months, according to Lea Widdice, MD, of the Cincinnati Children’s Hospital Medical Center, and colleagues.
One key factor that affected completion rates was race — white women and girls were more likely to finish that series than their black counterparts, Widdice and colleagues reported in the January issue of Pediatrics.
That finding is concerning, the researchers argued, because it may exacerbate existing racial disparities in cervical cancer.
While the pivotal clinical trials showed almost complete efficacy in preventing anogenital pre-cancers caused by human papillomavirus vaccine types 16 and 18, the investigators noted, the trials also had excellent compliance.
But for adolescents, timely compliance may be difficult and may lead to sub-optimal vaccine completion rates, they reported.
To examine the issue, Widdice and colleagues looked at medical records of all nine- to 26-year-old female patients at their institution who got their first dose of vaccine in the first two years after it became available.
The primary endpoint — based on Advisory Committee for Immunization Practices recommendations — was defined as the patient getting all three doses within 213 days, or about seven months. The secondary endpoint, based on the prescribing information, was all three doses within 365 days.
Overall, they found:
- 3,297 girls and women got at least one dose of the vaccine between November 2006 and June 2008.
- Of those, 471 completed the series within seven months and 914 did so within 12 months — 14.3% and 27.7%, respectively.
My comment…. to this Merck sponsored study…
One week ago SANE Vax researcher, Janny Stokvis of the Netherlands reported the latest VAERS data on deaths and injury from the HPV vaccines.
Those numbers stood at:
20,575 adverse reactions
352 reports of abnormal pap smears post vaccination
89 reported deaths (plus 5 reports submitted to the FDA obtained by Judicial Watch under the Freedom of Information Act (FOIA) now missing from VAERS)
As of December 13, 2010 new reports state:
20,915 adverse injuries – an increase of 340 adverse events in one week.
370 reports of abnormal pap smears post vaccination (18 new cases submitted in a week, three are related to Cervarix)
Reported deaths remain the same – 89 reported deaths (plus 5 reports submitted to the FDA obtained by Judicial Watch under the Freedom of Information Act (FOIA) now missing from VAERS)
Isn’t it possible that one of the reasons girls do not finish the vaccine series is because they are experiencing adverse reactions?
Has anyone taken the time to ask them?